PPARγ agonist 19

• Description :

  PPARγ agonist 19 (Compound 5e) is a PPARγ agonist. PPARγ agonist 19 has an IC50 of 11.27 μM against COX-1 and an IC50 of 0.05 μM against COX-1. PPARγ agonist 19 increases glucose uptake in rat hemidiaphragm assay and is superior to pioglitazone (HY-13956) . PPARγ agonist 19 alleviates hyperglycemia and insulin resistance in an in vivo model of type 2 diabetes in rats and protects against renal and lipidemia damage caused by metabolic dysfunction[1].

• UNSPSC :

  12352005

• Target :

  COX; PPAR

• Related Pathways :

  Cell Cycle/DNA Damage; Immunology/Inflammation; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

• Field of Research :

  Metabolic Disease

• Smiles :

  O=S(C1=CC=C(N2N=NC(COC3=CC=C(/C=C(SC(N4)=S)/C4=O)C=C3OC)=C2)C=C1)(N)=O

• Molecular Formula :

  C20H17N5O5S3

• Molecular Weight :

  503.57

• References & Citations :

  [1]Perihan A. Elzahhar, et al. Multi-Target Glitazones for Modulating Peroxisome Proliferator-Activated Receptor-γ, Cyclooxygenase-2, and Carbonic Anhydrases for the Management of Metabolic Dysfunction. ACS. Vol 8/Issue 6. 2025.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  COX-1; COX-2; PPARγ